Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
- Conditions
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- University Hospital Tuebingen
- Registration Number
- NCT00289445
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2018-10-24
- Target Recruit Count
- 249
- Registration Number
- NCT00276744
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study of Mitomycin C, Irinotecan, and Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00271011
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT00265863
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 80
- Registration Number
- NCT00201747
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT00192049
- Locations
- 🇮🇱
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Tel hashomer, Israel
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 280
- Registration Number
- NCT00148395
- Locations
- 🇩🇪
Klinikum Kassel GmbH, Kassel, Germany
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research UK
- Registration Number
- NCT00004209
- Locations
- 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
🇬🇧Royal Marsden NHS Trust, London, England, United Kingdom
Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus
- Conditions
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT00002993
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT00003003
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.